![We want to work with global innovation leaders in disruptive technologies](https://cdn.magzter.com/1444374281/1641374264/articles/F6B1LYoY11641552329610/We-want-to-work-with-global-innovation-leaders-in-disruptive-technologies.png)
How do you define growth-driven investment strategies fostering transformative startups and technologies in major APAC markets?
Asia is hitting a sweet spot for companies and investors alike. However, the opportunities for growth within the startup ecosystem also mean that there cannot be a one-size-fits-all investment strategy. Investors must be able to tailor their strategies across specific startups, technologies and even across countries. For example, in Southeast Asia, most ecosystems are still in the early development phase, but countries such as Singapore, Malaysia and Indonesia have already entered the next phase, given their size and rapid development. Singapore, in particular, has become a true leader in the region due to its supportive government policies and dedicated programmes contributing to the success of its startup ecosystem.
Asia holds major growth share within disruptive fields such as additive manufacturing, sustainable nutrition and health-tech solutions. Every investment is a new opportunity for collaboration and breakthroughs. Evonik Venture Capital has already executed a total of eight direct and fund investments in Asia since 2018.
How does Evonik evaluate market dynamics and operational growth in Asian Biomedical R&D and early-stage companies for investment allocations?
هذه القصة مأخوذة من طبعة BioSpectrum Asia Jan 2022 من BioSpectrum Asia.
ابدأ النسخة التجريبية المجانية من Magzter GOLD لمدة 7 أيام للوصول إلى آلاف القصص المتميزة المنسقة وأكثر من 9,000 مجلة وصحيفة.
بالفعل مشترك ? تسجيل الدخول
هذه القصة مأخوذة من طبعة BioSpectrum Asia Jan 2022 من BioSpectrum Asia.
ابدأ النسخة التجريبية المجانية من Magzter GOLD لمدة 7 أيام للوصول إلى آلاف القصص المتميزة المنسقة وأكثر من 9,000 مجلة وصحيفة.
بالفعل مشترك? تسجيل الدخول
![Korea develops micro-structured artificial lung model using bioprinting technology](https://reseuro.magzter.com/100x125/articles/11639/1818888/DFpRQAo0P1725966376960/KOREA-DEVELOPS-MICROSTRUCTURED-ARTIFICIAL-LUNG-MODEL-USING-BIOPRINTING-TECHNOLOGY.jpg)
Korea develops micro-structured artificial lung model using bioprinting technology
A team of Korean researchers has made a breakthrough that will greatly enhance the efficiency of respiratory disease research, garnering attention.
![Philips names Ling Liu as Chief Region Leader of Greater China](https://reseuro.magzter.com/100x125/articles/11639/1818888/rwjSFmWw51725966335985/PHILIPS-NAMES-LING-LIU-AS-CHIEF-REGION-LEADER-OF-GREATER-CHINA.jpg)
Philips names Ling Liu as Chief Region Leader of Greater China
Royal Philips, a global leader in health technology, has announced the appointment of Ling Liu as the Chief Region Leader of Philips Greater China.
![PW Skills launches School of Healthcare to solve India's critical shortage of medical professionals](https://reseuro.magzter.com/100x125/articles/11639/1818888/2XjPy6IPH1725966291866/PW-SKILLS-LAUNCHES-SCHOOL-OF-HEALTHCARE-TO-SOLVE-INDIAS-CRITICAL-SHORTAGE-OF-MEDICAL-PROFESSIONALS.jpg)
PW Skills launches School of Healthcare to solve India's critical shortage of medical professionals
PW Skills, the upskilling vertical of Physics Wallah (PW) has announced the launch of School of Healthcare across five cities in India, namely, Noida, Indore, Lucknow, Patna and Delhi.
![Australian biotech incubator Proto Axiom announces $20 M Series B first close](https://reseuro.magzter.com/100x125/articles/11639/1818888/jOEn5CpJA1725966221956/AUSTRALIAN-BIOTECH-INCUBATOR-PROTO-AXIOM-ANNOUNCES-20-M-SERIES-B-FIRST-CLOSE.jpg)
Australian biotech incubator Proto Axiom announces $20 M Series B first close
Proto Axiom, the Australian biomedical technology incubator, has announced a $20 million first close of its targeted $30 million Series B, to bolster Australia's biotechnology sector through increased intellectual property (IP) retention.
![Biogen, Beckman Coulter and Fujirebio to develop new tests for tau pathology](https://reseuro.magzter.com/100x125/articles/11639/1818888/k-dotQsaC1725966168942/BIOGEN-BECKMAN-COULTER-AND-FUJIREBIO-TO-DEVELOP-NEW-TESTS-FOR-TAU-PATHOLOGY.jpg)
Biogen, Beckman Coulter and Fujirebio to develop new tests for tau pathology
Biogen Inc., Beckman Coulter, Inc. (both based in the US) and Japan-based Fujirebio have announced a collaboration to potentially identify and develop blood-based biomarkers for tau pathology in the brain and to potentially clinically advance and potentially commercialise new tests for tau pathology in Alzheimer’s disease (AD).
![Pfizer upgrades pharma production plant in Melbourne](https://reseuro.magzter.com/100x125/articles/11639/1818888/a90Fb5AtA1725966130895/PFIZER-UPGRADES-PHARMA-PRODUCTION-PLANT-IN-MELBOURNE.jpg)
Pfizer upgrades pharma production plant in Melbourne
Australia is stepping up to the global fight against antimicrobial resistance, as Pfizer Australia announces a major upgrade to its manufacturing facility in Melbourne, Victoria.
![mRNA as novel active ingredient - Plasmid Factory providing the template for tomorrow's vaccines](https://reseuro.magzter.com/100x125/articles/11639/1818888/3XsL9TLoe1725965927637/MRNA-AS-NOVEL-ACTIVE-INGREDIENT-PLASMID-FACTORY-PROVIDING-THE-TEMPLATE-FOR-TOMORROWS-VACCINES.jpg)
mRNA as novel active ingredient - Plasmid Factory providing the template for tomorrow's vaccines
PlasmidFactory GmbH was founded in 2000 in Bielefeld/Germany with 4 employees. In the meantime, under the founder and managing director Dr. Martin Schleef, the company has become a well-known contract manufacturer (CDMO) for plasmid and minicircle DNA. Today, PlasmidFactory has ~50 highly qualified employees, and has established a GMP manufacturing facility.
!["Our priorities will include identifying and understanding the challenges while engaging regularly with industry leaders to address their concerns"](https://reseuro.magzter.com/100x125/articles/11639/1818888/2C1_cPJeY1725965820376/OUR-PRIORITIES-WILL-INCLUDE-IDENTIFYING-AND-UNDERSTANDING-THE-CHALLENGES-WHILE-ENGAGING-REGULARLY-WITH-INDUSTRY-LEADERS-TO-ADDRESS-THEIR-CONCERNS.jpg)
"Our priorities will include identifying and understanding the challenges while engaging regularly with industry leaders to address their concerns"
K Raja Bhanu has been elevated from Executive Director to Director General of the Pharmaceuticals Export Promotion Council of India (Pharmexcil), effective July 1, 2024. Bhanu brings a wealth of experience from his distinguished career in drug control and regulation. He has a proven track record in advancing drug quality, safety, and regulatory compliance. His leadership at the Drug Control Administration (DCA) was marked by significant initiatives that enhanced drug regulation standards and reinforced India's pharmaceutical reputation globally. In his current role, Bhanu is set to drive the expansion of India's pharmaceutical exports, boost global competitiveness, and adeptly navigate the complexities of international regulations, leveraging his extensive expertise to foster industry growth and global prominence. In an interaction with BioSpectrum, he shared his plans on addressing many challenges before the Indian pharma industry to stay compliant with international regulations. Edited excerpts:
!["Australia has long been a global leader in research, yet our biotech sector has not lived up to its full potential"](https://reseuro.magzter.com/100x125/articles/11639/1818888/fVNypnxPx1725965751346/AUSTRALIA-HAS-LONG-BEEN-A-GLOBAL-LEADER-IN-RESEARCH-YET-OUR-BIOTECH-SECTOR-HAS-NOT-LIVED-UP-TO-ITS-FULL-POTENTIAL.jpg)
"Australia has long been a global leader in research, yet our biotech sector has not lived up to its full potential"
Australia's first true biotech incubator, Proto Axiom, has secured $20 million in the first close of its $30 million Series B round to strengthen the nation's biotech sector through greater IP retention. Anthony Liveris, CEO of Proto Axio discusses the incubator's selection criteria, identifying the most promising biotech trends for global health, and outlining the key strengths that make Australian biotech globally competitive. Edited excerpts:
![Unleashing Innovative Wound Care Solutions](https://reseuro.magzter.com/100x125/articles/11639/1818888/go6IqPK4W1725965621357/UNLEASHING-INNOVATIVE-WOUND-CARE-SOLUTIONS.jpg)
Unleashing Innovative Wound Care Solutions
The incidence of wounds is rising, especially in the Asia-Pacific (APAC) region. In Australia alone, 420,000 individuals are impacted by chronic wounds, leading to direct healthcare costs of AUD $3 billion, representing 2 per cent of the country's total healthcare expenditure. Similarly, data from Singapore between 2000 and 2017 revealed that the incidence of wounds among hospitalised adults was 300 per 100,000 for those over 18 and 800 per 100,000 for those over 50. Let's explore further.